Bayer, BioNxt Solutions, FamiCord AG – Undiscovered gems with strong growth potential

FamiCord AG – Pure Growth

Poland has transformed itself into Europe's growth engine in recent years. This presents opportunities for investors because, despite the upswing, Polish companies are still considered undervalued gems compared to their competitors.

FamiCord owns Europe's largest umbilical cord blood bank and ranks third worldwide. The Company was formed in 2021 through the merger of Vita 34 and the Polish company PBKM. Today, it operates an international network with over 1,500 partner clinics, 15 laboratories across Europe, and a new facility in Dubai. In total, FamiCord stores over 1 million units of umbilical cord blood.

With a market share of 67% in its target regions and an innovative subscription model instead of traditional prepayments, FamiCord clearly stands out from the competition. This not only ensures predictable, recurring revenue—in the B2C segment alone, revenue has increased by 165% since 2016—but also keeps the cancellation rate below 10%.

In addition to serving families, FamiCord also generates revenue from services for biotech companies and clinics. Through its new business segment of placenta banking and CAR-T cancer research via its subsidiary FamiCordTx, the Company is increasingly positioning itself as an innovative biotech player.

2025 started with a revenue jump of over 19% in the first quarter. The EBITDA margin reached a record high of 12.4%. Revenue of up to EUR 95 million is expected for the full year. Despite demographic challenges in Europe, FamiCord is scoring points with international expansion, stable cash flow, and a strong market position.

BioNxt Solutions – Significant opportunities

Canadian biotech company BioNxt Solutions is pursuing a clear approach. The goal is not to develop new active ingredients, but to improve their delivery. With sublingual dissolvable films and transdermal patches, the Company aims to make access to established medications easier for patients, addressing a multi-billion-dollar problem, as many tablets currently break down too early in the body or are difficult to take.

The focus is on the sublingual cladribine formulation for multiple sclerosis (MS). Almost 3 million people worldwide are affected, many of whom suffer from swallowing difficulties. The market is huge: in 2024, global revenue from MS drugs totaled around USD 21.1 billion, and this figure is expected to increase to just under USD 39 billion by 2032. Patent expiries for blockbusters such as Biogen's Tysabri and Novartis' Gilenya are opening up additional scope for new providers. Merck's reference drug, Mavenclad, generated revenue of approximately EUR 1 billion in 2023.

A major advantage is the lower regulatory risk. Since cladribine has long been approved, BioNxt only needs to demonstrate bioequivalence. The decisive study is set to start soon. At the same time, the Company is building up a strong IP portfolio. Patent applications have recently been accepted in Europe and Eurasia, and a fast-track procedure is already underway in the US. In addition to the cladribine project, BioNxt is developing a platform technology that makes active ingredients more efficient and bypasses first-pass metabolism.

A steady stream of news, a pipeline of rare diseases such as myasthenia gravis, a globally growing market for drug delivery systems, and the possibility of a takeover by Big Pharma offer enormous upside potential for this innovative company. In their latest study, analysts at Black Research set a price target of EUR 2.20. BioNxt shares are currently trading at EUR 0.65.

Bayer – The air is getting thinner

Bayer shares have outperformed by over 62% since their low for the year at the beginning of April. The share price even touched the EUR 30 mark, but had to admit defeat in the face of significant resistance. The trend-following indicator MACD and the RSI slipped into the red zone last week, making further price losses likely. The next support zone is at EUR 25.30.

The share price was negatively impacted by the announcement that the Leverkusen-based company presented the results of the Phase III VICTOR study on Vericiguat, a promising drug for the treatment of chronic heart failure with reduced ejection fraction, at the ESC Congress 2025. The primary endpoint of the study, a combination of cardiovascular death or hospitalization for heart failure, was not achieved.

Nevertheless, there were positive signs. There were fewer cardiovascular deaths and lower overall mortality in the vericiguat group than in the placebo group. The safety profile was also consistent with previous study results. It is also worth noting that the VICTOR study was conducted in a highly stable patient population. 83% of participants received at least three therapies, and almost half had never been hospitalized for heart failure.

Bayer shares failed to break through the EUR 30 mark, and weak study results were published. Polish company FamiCord AG is expanding into non-European countries. Analysts see BioNxt as a candidate for multiplication.